Prediction of Response Of horMOnal Treatment in advanced and recurrent Endometrial cancer
Phase 4
Recruiting
- Conditions
- endometrial canceruterine cancer10046828
- Registration Number
- NL-OMON54286
- Lead Sponsor
- Radboud Universitair Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 130
Inclusion Criteria
• Advanced stage (FIGO stage III and IV) and recurrent endometrial cancer
• All histologic types of endometrial carcinoma
• Planned treatment with any type of hormonal therapy
• Biopsy taken within 120 days prior to start of hormonal therapy with no
intercurrent therapy between biopsy and start of hormonal therapy
• In metastatic EC, histological sampling of one distant metastasis is
recommended
Exclusion Criteria
• Adjuvant hormonal therapy immediately started after surgery
• Synchronous use of hormonal therapy for other indications
• Endometrial sarcoma or endometrial stroma cell sarcoma
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Response rate, progression free survival (PFS) and clinical benefit rate (CBR). </p><br>
- Secondary Outcome Measures
Name Time Method <p>Health-related quality of life</p><br>